Publications

18

Jul, 2015

“But it’s my story”: exploring the experience and effect of telling children how they have acquired HIV

 

Authors:  Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S,  Rhodes T and the BREATHER Trial Team.

Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.

Read

14

Jul, 2015

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission

 

Authors: Klein N, Palma P, Luzuriaga K, et al.

Published in: Lancet Infect Dis. 2015;15(9):1108-1114.

Abstract: From the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV cure hinted at by the Mississippi baby experience, paediatric HIV infection has been pivotal to our understanding of HIV pathogenesis and management. Daily medication and indefinite antiretroviral therapy is recommended for children infected with HIV. Maintenance of life-long adherence is difficult and the incidence of triple-class virological failure after initiation of antiretroviral therapy increases with time. This challenge shows the urgent need to define novel strategies to provide long-term viral suppression that will allow safe interruption of antiretroviral therapy without viral rebound and any associated complications. HIV-infected babies treated within a few days of birth have a unique combination of a very small pool of integrated viruses, a very high proportion of relatively HIV resistant naive T cells, and an unparalleled capacity to regenerate an immune repertoire. These features make this group the optimum model population to investigate the potential efficacy of immune-based therapies. If successful, these investigations could change the way we manage HIV infection.

Read

1

Jul, 2015

“But it’s my story”: exploring the experience and effect of telling children how they have acquired HIV

 

Authors: Seeley J on behalf of the Bernays S, Paparini S, Namukwaya Kihika S,  Rhodes T and the BREATHER Trial Team.

Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.

Read

1

Jul, 2015

Young people, clinical trials and ‘the HIV experience’: What can similarities across time and place tell us about growing up with HIV?

 

Author: Paparini S on behalf of Bernays S, Seeley S, Rhodes T, Namukwaya Kihika S,Kawuma-Kigawa R, Nakyambadde H, Kabajaasi O and the BREATHER Trial Team.

Published in: 3rd International ASSHH Conference, Stellenbosch, South Africa, 6-9 July 2015.

Read

1

Jul, 2015

‘I am scared of getting caught up in my lie’: challenges to self-reported adherence for young people living with HIV; accepted for presentation at AIDS Impact

 

Authors: Bernays S, Seeley J, Paparini S, Rhodes T and the ARROW and BREATHER trial teams

Published in: AIDS Impact, Amsterdam 28-31 July, 2015 (abstract 3435)

Read

30

Jun, 2015

The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children

 

Authors: Palma P, Foster C, Rojo P, et al.

Published in: J Virus Erad. 2015;1(3):134-139.

Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric antifungal stewardship programmes.

Read

19

Apr, 2015

Once- versus twice-daily lopinavir/ritonavir in HIV-1 infected children: a randomised controlled trial (KONCERT/PENTA18/ANRS150).

 

Published in: AIDS 2015, 29:2447-2457

Read

1

Mar, 2015

Once- versus twice-daily lopinavir/ritonavir in HIV-1 infected children: a randomised controlled trial (KONCERT/PENTA18/ANRS150).

 

Published in: AIDS 2015, 29:2447-2457

Read

28

Feb, 2015

The PENTA 2016 update of the guidelines for the treatment of paediatric HIV-1 infection 2015

 

The PENTA 2015 guidelines (hyperlink to 2015 guidelines) are due for further update, focussing on first and second line treatment options, in 2017.

Read

23

Feb, 2015

ART With Weekends Off Is Noninferior to Continuous ART in Young People on EFV+2NRTI

 

For HIV-1 infected young people (YP) facing lifelong ART, short cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity and better adherence, as well as cost savings.

Author: Karina M. Butler on behalf of the BREATHER trial team

Published in: CROI 2015, Seattle, USA, Feb 23 -26 2015.

Read